Assembly Biosciences

89 articles with Assembly Biosciences

• Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021

  6/9/2021

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that three abstracts have been accepted for presentation during the International Liver Congress™ 2021, the Annual Meeting of the European Association for the Study of the Liver (EASL) taking place virtually June 23-26, 2021.

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021

  6/4/2021

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to six new employees to purchase an aggregate of 106,520 shares of the Company’s common stock with an exercise price of $4.03 per share, the closing price of Assembly Bio’s common stock on June 1, 2021.

• Dr. Lisa Johnson-Pratt Joins Assembly Biosciences Board of Directors

  5/24/2021

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced that Lisa Johnson-Pratt, M.D., has joined the company’s board of directors.

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 07, 2021

  5/7/2021

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 25,000 shares of the Company’s common stock with an exercise price of $4.16 per share, the closing price of Assembly Bio’s common stock on May 3, 2021.

• Assembly Biosciences Reports First Quarter 2021 Financial Results and Recent Updates

  5/6/2021

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, reported financial results and recent updates for the first quarter ended March 31, 2021.

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 05, 2021

  3/5/2021

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 26,000 shares of the Company’s common stock with an exercise price of $5.05 per share, the closing price of Assembly Bio’s common stock on March 1, 2021.

• Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus

  2/26/2021

  Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced the initiation of a Phase 2 clinical trial of Assembly Bio’s investigational hepatitis B virus (HBV) core inhibitor candidate

• Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection

  2/25/2021

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that it is foregoing its plans to initiate Phase 3 registrational studies of vebicorvir

• Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights

  2/25/2021

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, reported financial results and recent highlights for the fourth quarter and year ended December 31, 2020.

• Assembly Bio Announces Upcoming Investor Events

  2/19/2021

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced two upcoming investor events:

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 05, 2021

  2/5/2021

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 38,000 shares of the Company’s common stock with an exercise price of $5.79 per share, the closing price of Assembly Bio’s common stock on February 1, 2021.

• Assembly Biosciences to Wind-Down Microbiome ProgramCompany will prioritize resources to focus on advancement of novel HBV therapeutic portfolio

  12/8/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that it will wind-down its microbiome program, enabling the company to prioritize resources and focus on the advancement of its pipeline of novel core inhibitors for chronic HBV.

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 04, 2020

  12/4/2020

  Assembly Biosciences, Inc. announced grants of stock options to three new employees to purchase an aggregate of 14,520 shares of the Company’s common stock with an exercise price of $5.66 per share, the closing price of Assembly Bio’s common stock on December 1, 2020.

• Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing

  11/17/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing

• Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators

  11/16/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of a novel class of hepatitis B virus (HBV) core protein modulators. Door Pharmaceuticals’ innovative discovery platform targets functions of core protein distinct from viral assembly and that have the potential to interfere with v

• Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™

  11/13/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that data from its HBV core inhibitor programs and related research will be highlighted during four poster sessions – including two late-breakers – at the 2020 American Association for the Study of Liver Diseases (AASLD

• Assembly Biosciences Reports Grant Under Nasdaq Listing Rule 5635(c)(4)

  11/6/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of stock options to a new employee to purchase 6,520 shares of the Company’s common stock with an exercise price of $14.75 per share, the closing price of Assembly’s common stock on November 2, 2020. The stock optio

• 

  Assembly Biosciences Falls Short with Hepatitis B Drug in Phase 2 Study

  11/6/2020

  Assembly Biosciences, Inc. provided an update on Nov. 5 of its ongoing Phase 2 extension study, Study 211, examining vebicorvir (VBR, or ABI-H0731) in patients with hepatitis B virus infection.

• Assembly Biosciences Reports Third Quarter 2020 Financial Results and Business Update

  11/5/2020

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, reported financial results and a business update for the third quarter ended September 30, 2020.

• Assembly Biosciences Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

  11/5/2020

  HBV field’sfirstcore inhibitor combination study to assess off-treatmentresponse has not achieved a meaningful rate ofsustained virologic response